(Q30971455)

27 June 2017

1 reference

title

Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family (English)

1 reference

27 June 2017

1 reference

1 reference

Shangary S

1

1 reference

27 June 2017

Johnson DE

series ordinal

2

1 reference

27 June 2017

publication date

1 August 2003

1 reference

27 June 2017

1 reference

27 June 2017

volume

17

1 reference

27 June 2017

issue

8

1 reference

27 June 2017

page(s)

1470-1481

1 reference

Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18.

27 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

21 January 2018

Regulators of cell death

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

The relationship between bcl-2 expression and response to chemotherapy in acute leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Preferential linkage of bcl-2 to immunoglobulin light chain gene in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Update on the biology of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Expression of Bcl-2 family of proteins in fresh myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Prognostic value of bcl-2 expression in invasive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Significance of Apoptosis and Apoptotic-Related Proteins, Bcl-2, and Bax in Primary Breast Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Loss of Bcl-2 expression correlates with tumour recurrence in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Involvement of the hepatocyte growth factor/scatter factor receptor c-met and of Bcl-xL in the resistance of oropharyngeal cancer to ionizing radiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

bax, but not bcl-2, influences the prognosis of human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Myeloid cell factor-1 is a critical survival factor for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Increased MCL-1 expression is associated with poor prognosis in ovarian carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

BCL2-mediated tumorigenicity of a human T-lymphoid cell line: synergy with MYC and inhibition by BCL2 antisense

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Increased cytotoxicity against B-chronic lymphocytic leukemia by cellular manipulations: potentials for therapeutic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Chemosensitisation of malignant melanoma by BCL2 antisense therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting anti-apoptotic genes upregulated after androgen withdrawal to delay androgen-independent progression and enhance chemosensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Bcl-X(L) antisense sensitizes human colon cancer cell line to 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Expression and role of Bcl-xL in human hepatocellular carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Modulation of apoptosis by endogenous Bcl-xL expression in MKN-45 human gastric cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Bcl-2 and bcl-xL antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Solution structure of the antiapoptotic protein bcl-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Structure of Bax: coregulation of dimer formation and intracellular localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Rendering a membrane protein soluble in water: a common packing motif in bacterial protein toxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Channel formation by antiapoptotic protein Bcl-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Comparison of the ion channel characteristics of proapoptotic BAX and antiapoptotic BCL-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Bcl-x(L) forms an ion channel in synthetic lipid membranes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Inhibition of Bax channel-forming activity by Bcl-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

BAX-dependent transport of cytochrome c reconstituted in pure liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

The Bcl-2 protein family: arbiters of cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Structure-function analysis of Bcl-2 protein. Identification of conserved domains important for homodimerization with Bcl-2 and heterodimerization with Bax.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Functional dissection of the human Bc12 protein: sequence requirements for inhibition of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

NH2-terminal BH4 domain of Bcl-2 is functional for heterodimerization with Bax and inhibition of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

A peptide sequence from Bax that converts Bcl-2 into an activator of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Proapoptotic protein Bax heterodimerizes with Bcl-2 and homodimerizes with Bax via a novel domain (BH3) distinct from BH1 and BH2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

A common binding site mediates heterodimerization and homodimerization of Bcl-2 family members

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

The BH3 domain of Bax is sufficient for interaction of Bax with itself and with other family members and it is required for induction of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Dimerization properties of human BAD. Identification of a BH-3 domain and analysis of its binding to mutant BCL-2 and BCL-XL proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Bax directly induces release of cytochrome c from isolated mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Cellular uptake of the tat protein from human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

In vivo protein transduction: delivery of a biologically active protein into the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Intercellular trafficking and protein delivery by a herpesvirus structural protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Intercellular delivery of functional p53 by the herpesvirus protein VP22.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Induction of apoptosis in prostate carcinoma cells by BH3 peptides which inhibit Bak/Bcl-2 interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Bad is a BH3 domain-containing protein that forms an inactivating dimer with Bcl-XL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Anti-cancer activity of targeted pro-apoptotic peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Biophysical characterization of recombinant human Bcl-2 and its interactions with an inhibitory ligand, antimycin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

A novel approach for characterizing protein ligand complexes: molecular basis for specificity of small-molecule Bcl-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

Involvement of the bcl-2 gene in human follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

7 January 2021

MCL-1, a member of the BLC-2 family, is induced rapidly in response to signals for cell differentiation or death, but not to signals for cell proliferation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

7 January 2021

Haematopoietic response and bcl-2 expression in patients with acute myeloid leukaemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

7 January 2021

High bax expression is a good prognostic indicator in acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

7 January 2021

Primary follicular lymphoma of the testis in childhood

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

7 January 2021

Clinicopathologic analysis of follicular lymphoma occurring in children

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

7 January 2021

Analysis of Bcl-2 protein expression in chronic lymphocytic leukemia. A comparison of three semiquantitation techniques

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

7 January 2021

Regulation of clinical chemoresistance by bcl-2 and bax oncoproteins in B-cell chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

7 January 2021

Bcl-2 expression in malignant melanoma and its prognostic significance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

7 January 2021

Immunohistochemically detectable bcl-2 expression in metastatic melanoma: association with survival and treatment response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

7 January 2021

Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

7 January 2021

Bcl-2/bax mRNA expression ratio as prognostic factor in low-grade urinary bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

7 January 2021

Bcl-2 and p53 expressions in invasive bladder cancers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

7 January 2021

Frequent expression of bcl-2 protein in solitary fibrous tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

7 January 2021

Bcl-x(L) is heterogenously expressed by acute myeloblastic leukaemia cells and is associated with autonomous growth in vitro and with P-glycoprotein expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

7 January 2021

Moderate activation of the apoptosis inhibitor bcl-xL worsens the prognosis in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

7 January 2021

Immunohistochemical analysis of Bcl-2, Bax, Bcl-X, and Mcl-1 expression in pancreatic cancers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

7 January 2021

Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

7 January 2021

Investigations of antisense oligonucleotides targeted against bcl-2 RNAs.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

7 January 2021

Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

7 January 2021

Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

7 January 2021

Antisense-mediated suppression of Bcl-2 highlights its pivotal role in failed apoptosis in B-cell chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

7 January 2021

BCL-2 antisense therapy in patients with non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

7 January 2021

bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

7 January 2021

Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

7 January 2021

Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

7 January 2021

Bcl-xl antisense treatment induces apoptosis in breast carcinoma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

7 January 2021

Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense BCL-XL and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

7 January 2021

Analysis of ribosyl-modified, mixed backbone analogs of a bcl-2/bcl-xL antisense oligonucleotide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

7 January 2021

Peptides derived from BH3 domains of Bcl-2 family members: a comparative analysis of inhibition of Bcl-2, Bcl-x(L) and Bax oligomerization, induction of cytochrome c release, and activation of cell death

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

7 January 2021

Regulation of apoptosis by BH3 domains in a cell-free system

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

7 January 2021

Bak BH3 peptides antagonize Bcl-xL function and induce apoptosis through cytochrome c-independent activation of caspases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

7 January 2021

The BH3 domain of BAD fused to the Antennapedia peptide induces apoptosis via its alpha helical structure and independent of Bcl-2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

7 January 2021

Tetrocarcins, novel antitumor antibiotics. I. Producing organism, fermentation and antimicrobial activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

7 January 2021

Tetrocarcins, novel antitumor antibiotics. II. Isolation, characterization and antitumor activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

7 January 2021

Tetrocarcins, new antitumor antibiotics. 3. Antitumor activity of tetrocarcin A

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

7 January 2021

Synthesis of tetrocarcin derivatives with specific inhibitory activity towards Bcl-2 functions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

7 January 2021

Stressful death of T-ALL tumor cells after treatment with the anti-tumor agent Tetrocarcin-A.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403029

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2403029

1 reference

Dimensions Publication ID

27 June 2017

1015469961

0 references

1 reference